EQUASHIELD®, a global leader in healthcare innovation, proudly announces the launch of CellSHIELD®, a groundbreaking device designed to transform cell and gene therapy manufacturing. Building on its proven expertise in CSTD technology, EQUASHIELD® brings the same trusted safety and containment principles to this new frontier. This fully closed, sterile, and disposable system is set to redefine industry standards, offering unparalleled safety, efficiency, and scalability.
Advancing Medical Treatments with Innovation
The device is particularly well-suited for common applications such as in-process testing and cell culture sampling, sterile fluid transfer between vessels, and air removal to eliminate bubbles, ensuring precision and reliability in critical manufacturing steps.
Key Features and Benefits
- Patient Safety and Quality: By maintaining sterility and biocontainment throughout the manufacturing process, CellSHIELD® upholds the highest standards of patient safety and product quality.
- Simplicity and Efficiency: Designed for ease of use, CellSHIELD® ensures simple, repeatable processes that reduce the risk of errors and improve operational efficiency, ultimately lowering costs.
- Minimal Training Required: Engineered for intuitive use, CellSHIELD® minimizes the need for extensive training, enabling faster onboarding and productivity.
- Proven CSTD Expertise: Leveraging EQUASHIELD®‘s expertise in Closed System Transfer Devices (CSTD), CellSHIELD® brings the same trusted safety and containment principles to cell and gene therapy manufacturing.
Also Read: Medical Manufacturing Technologies (MMT) Expands Bonding Capabilities With Acquisition of Innova Design
Executive Insights
A leading cell therapy CDMO shared their experience with CellSHIELD®: “We see such low volume loss with CellSHIELD®, that once we switch people over, there really is no comparison. Little to no volume loss, less than 0.1%,” said a representative from the company.
“CellSHIELD® represents a significant leap forward in cell and gene therapy manufacturing,” said Matt Stuckert, General Manager of EQUASHIELD®. “Our mission has always been to innovate and provide solutions that address the most pressing challenges in healthcare. With CellSHIELD®, we are empowering manufacturers to deliver life-saving therapies more efficiently and safer than ever before.”
Jason Dutcher, Director of Strategic Accounts, added, “The launch of CellSHIELD® underscores our commitment to advancing medical treatments through cutting-edge technology. This device not only enhances safety and efficiency, but also supports the scalability required to meet the growing demand for cell and gene therapies.”
SOURCE: PRNewswire